Pharmaceutical industry – Page 20
-
BusinessDrugmaker blocks Nevada execution
Alvogen obtains a restraining order to delay US prisoner’s execution, saying Nevada state obtained its sedative midazolam via ‘subterfuge’
-
BusinessJ&J and the question of shadow research
Former academic researcher who found that talc is not carcinogenic admits that J&J funded his work, but says that fact is immaterial
-
BusinessGene therapy gathers pace
Sarah Houlton charts the evolution, challenges and opportunities of cell and gene therapy
-
NewsFears that US 'right to try' law could put patients at risk
Legislation will give terminally ill patients the option of taking medicines that have had little testing
-
BusinessUS senators launch probe of Novartis’ payments to Trump lawyer
Congress demands info from Novartis about its $1.2m in outflows to Michael Cohen, just as it was negotiating payments for its cancer drug
-
BusinessTrump lays out plan to slash drug costs
White House strategy to reduce pharmaceutical prices faces backlash from the industry, which cautions against the ‘far-reaching’ proposals
-
BusinessTakeda set to swallow Shire
Shire’s US revenue and rare diseases portfolio grab Japanese firm’s attention
-
ArticleAre polymer medicines viable therapeutics?
Combining small-molecule medicines with polymers could offer big rewards for pharmaceutical researchers
-
ArticleThe dark side of chemical patents
Unloved, ignored and misunderstood but could all that change?
-
FeatureUnderstanding Alzheimer’s
After hundreds of failed drug candidates, James Mitchell Crow asks if this is the last roll of the dice for the amyloid theory of Alzheimer’s disease
-
Feature3D printing in pharma
Nina Notman explores how 3D printing is carving out a niche for itself in the pharmaceutical industry
-
BusinessDeal protects world’s biggest selling drug from biosimilar erosion
AbbVie and Samsung Bioepis resolve patent litigation over arthritis drug Humira
-
BusinessIndia creates national drugs database to address supply and quality issues
Regulatory body takes steps to reform how it manages and monitors pharmaceuticals
-
BusinessNovartis’ $8.7bn AveXis deal shows gene therapy appeal
Acquisition indicates the value of potentially permanent cures for inherited diseases
-
-
ResearchSolving the crystal maze
Workflow swaps gut feelings for data when designing continuous crystallisation processes
-
BusinessFit for repurpose
Drugs that can be used for new indications offer a potentially cheaper pathway – but only if the investors can recoup their costs
-
FeatureCuba: socialism, cigars and biotech
Nina Notman learns how biotechnology could potentially overtake cigars as Cuba’s most famous export
-
NewsBrexit analysis predicts chemical industry contraction
UK government forced to publish briefing that suggests production will fall by up to 16%
-
ArticlePharma and academia: a recipe for success
More big pharmaceutical companies are collaborating with universities